论文部分内容阅读
由日本开发的链球菌制剂Picibanil(OK-432)是迄今为止最强的生物效应调节剂(BRM)之一,在14届国际化疗会议上,有120篇以上的论文论述本品的作用机制及临床研究情况,一致给予较高的评价。Piciba-nil 除可激活人体各种免疫因子,主要增强各种天然杀伤(NK)细胞活力,杀伤癌细胞外,并可促进肝、肺、脾、骨髓中NK 细胞的产生和成熟速率,亦可将静止中的周围血淋巴细胞激活成肿瘤杀伤细胞。实验证实,用药
Developed by Japan, the Streptococcus preparation Picibanil (OK-432) is one of the strongest biological effect modifiers (BRM) to date. At the 14th International Conference on Chemotherapy, more than 120 papers discussed the mechanism of action of the product. The clinical research situation was consistently given higher evaluation. In addition to activating various human immune factors, Piciba-nil enhances the viability of various natural killer (NK) cells, kills cancer cells, and promotes the production and maturation rate of NK cells in liver, lung, spleen, and bone marrow. The resting peripheral blood lymphocytes are activated into tumor-killing cells. Experiment confirmed that medication